Interferon lambda-3 is not associated with clinical outcome in patients with HCV-induced compensated cirrhosis: A long-term cohort study

Antiviral Research

Volumn 113, Issue , 2015, Pages 27-32

  Bruno, Savino ^a   Thompson, Alex J ^b,c   Critelli, Rosina ^d   Crosignani, Andrea ^e   Rossi, Sonia ^a   De Lisi, Stefania ^a   Cariani, Elisabetta ^f   Zermiani, Paola ^e   Vaira, Valentina ^g   Boccaccio, Vincenzo ^a   Maisonneuve, Patrick ^h   Villa, Erica ^d  

^a Department of Internal Medicine AO Fatebenefratelli e Oftalmico ^*  (Italy)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f Ospedale Civile S Agostino Estense   (Italy)

^g FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^h EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

IFN based therapy; IFN 3 polymorphism; Outcome of compensated cirrhosis

Indexed keywords

ALBUMIN; INTERFERON; INTERFERON LAMBDA 3; INTERLEUKIN 28B; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CAUSE OF DEATH; CLINICAL ASSESSMENT; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; DNA POLYMORPHISM; FEMALE; FOLLOW UP; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER GRAFT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; AGED; DRUG EFFECTS; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; LIVER TRANSPLANTATION; LONGITUDINAL STUDY; TREATMENT OUTCOME; VIROLOGY;

HEPATITIS C VIRUS;

AGED; ANTIVIRAL AGENTS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; INTERLEUKINS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

EID: 84913534851     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2014.11.002     Document Type: Article

References (26)

1. Bedossa, P., Poynard, T., 1996. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR cooperative study group. Hepatology 24, 289-293.
2. Bochud, P.Y., Bibert, S., Kutalik, Z., et al.Swiss Hepatitis C cohort study group; ANRS HC EP 26 Genoscan study group, 2012. IL28B alleles associated with poor hepatitis C virus clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology 55, 384-394.
3. Bruix, J., Sherman, M., Llovet, J.M., et al.EASL panel of experts on HCC, 2001. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European association for the study of the liver. J. Hepatol. 35, 421-430.
4. Bruno, S., Zuin, M., Crosignani, A., et al., 2009. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study. Am. J. Gastroenterol. 104, 1147-1158.
5. Bruno, S., Shiffman, M.L., Roberts, S.K., et al., 2010. Efficacy and safety of peg-interferon alfa-2a (40 KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis.2010. Hepatology 51, 388-397.
6. Cariani, E., Critelli, R., Rota, C., et al., 2011. Interleukin 28B genotype determination using DNA from different sources: a simple and reliable tool for the epidemiological and clinical characterization of hepatitis C. J. Virol. Methods 178, 235-238.
7. Di Marco, V., Bronte, F., Calvaruso, V., et al., 2012. IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. Haematologica 97, 679-686.
8. Di Marco, V., Calvaruso, V., Grimaudo, S., et al., 2013. Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices. J. Viral Hepat. 20, 113-121.
9. Fabris, C., Falleti, E., Cussigh, A., et al., 2011. IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. J. Hepatol. 54, 716-722.
10. Ge, D., Fellay, J., Thompson, A.J., et al., 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 17 (461), 399-401.
11. Huang, H., Shiffman, M.L., Friedman, S., et al., 2007. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology 46, 297-306.
12. Kamath, P.S., Wiesner, R.H., Malinchoc, M., et al., 2001. A model to predict survival in patients with end-stage liver disease. Hepatology 33, 464-470.
13. Kondo, F., Wada, K., Nagato, Y., et al., 1989. Biopsy diagnosis of well-differentiated hepatocellular carcinoma based on new morphologic criteria. Hepatology 9, 71-75.
14. Lauer, G., Walker, B., 2001. Hepatitis C virus infection. N. Engl. J. Med. 345, 41-52.
15. Mangia, A., Thompson, A.J., Santoro, R., et al., 2010. An IL28B polymorphism determines treatment response of hepatitis c virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 139, 821-827.
16. Marabita, F., Aghemo, A., De Nicola, S., et al., 2011. Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology 54, 1127-1134.
17. Marmo, R., Romano, M., De Sio, I., et al., 1983. Decision-making model for a noninvasive diagnosis of compensated liver cirrhosis. Ital. J. Gastroenterol. 25, 1-8.
18. Missiha, S.B., Ostrowsky, M., Heathcote, E.J., 2008. Disease progression in chronic hepatitis C: modifiable and non modifiable factors. Gastroenterology 134, 1699-1714.
19. Mottola, L., Cenderello, G., Piazzolla, V.A., et al., 2014. Interleukin-28B genetic variants in untreated Italian HCV-infected patients: a multicentre study. Liver Int.. http://dx.doi.org/10.1111/liv.12630 (Epub ahead of print).
20. Patin, E., Kutalik, Z., Guergnon, J., et al.Swiss Hepatitis C cohort study group; International Hepatitis C Genetics Consortium; French ANRS HC EP 26 Genoscan study group, 2012. Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. Gastroenterology 143, 1244-1252.
21. Powell, E.E., Edwards-Smith, C.J., Hay, J.L., et al., 2000. Host genetic factors influence disease progression in chronic hepatitis. Hepatology 31, 828-833.
22. Rauch, A., Kutalik, Z., Descombes, P., et al., 2010. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138, 1338-1345.
23. Silini, E., Bono, F., Cividini, A., et al., 1995. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. Hepatology 21, 285-290.
24. Thompson, A.J., Muir, A.J., Sulkowski, M.S., et al., 2010. Interleukin 28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 139, 120-129.
25. Thompson, A.J., Clark, P.J., Fellay, J., et al., 2010. IL28B genotype is not associated with advanced hepatic fibrosis in chronic hepatitis C patients enrolled in the IDEAL study. Hepatology 52 (Suppl. 4), 437-438.
26. Wai, C.T., Greenson, J.K., Fontana, R.J., et al., 2003. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38, 518-526.